NatureSystems BiologyPeer-reviewed journal article
The natural diversity of the yeast proteome reveals chromosome-wide dosage compensation in aneuploids
Julia MuenzneriD, Pauline TrébulleiD, Federica AgostiniiD, Henrik ZauberiD, Christoph B. MessneriD, Martin StegeriD, Christiane Kilian, Kate LauiD, Natalie BartheliD, Andrea D. LehmanniD, Kathrin Textoris‐TaubeiD, Élodie Caudal, Anna-Sophia EggeriD, Fatma Amari, Matteo De ChiaraiD, Vadim DemicheviD, Toni Ingolf GossmanniD, Michael MüllederiD, Gianni LitiiD, Joseph SchachereriD, Matthias SelbachiD, Judith G. BermaniD, Markus RalseriD
Abstract
Aneuploidy, an imbalance in chromosome copy numbers, causes genetic disorders, and drives cancer progression, drug tolerance, and antimicrobial resistance. While aneuploidy can confer stress resistance, it is not well understood how cells overcome the fitness burden caused by aberrant chromosomal copy numbers. Studies using both systematically generated 1-5 and natural aneuploid yeasts 6-8 triggered an intense debate about the role of dosage compensation, concluding that aneuploidy is transmitted to the transcriptome and proteome without significant buffering at the chromosome-wide level, and is, at least in lab strains, associated with significant fitness costs. Conversely, systematic sequencing and phenotyping of large collections of natural isolates revealed that aneuploidy is frequent and has few - if any - fitness costs in nature 9. To address these discrepant findings at the proteomic level, we developed a platform that yields highly precise proteomic measurements across large numbers of genetically diverse samples, and applied it to natural isolates collected as part of the 1011 genomes project 9. For 613 of the isolates, we were able to match the proteomes to their corresponding transcriptomes and genomes, subsequently quantifying the effect of aneuploidy on gene expression by comparing 95 aneuploid with 518 euploid strains. We find, as in previous studies, that aneuploid gene dosage is not buffered chromosome-wide at the transcriptome level. Importantly, in the proteome, we detect an attenuation of aneuploidy by about 25% below the aneuploid gene dosage in natural yeast isolates. Furthermore, this chromosome-wide dosage compensation is associated with the ubiquitin-proteasome system (UPS), which is expressed at higher levels and has increased activity across natural aneuploid strains. Thus, through systematic exploration of the species-wide diversity of the yeast proteome, we shed light on a long-standing debate about the biology of aneuploids, revealing that aneuploidy tolerance is mediated through chromosome-wide dosage compensation at the proteome level.
- Citations
- 82
- FWCI
- 8.95
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- No evidence for whole-chromosome dosage compensation or global transcriptomic expression differences in spontaneously-aneuploid mutation accumulation lines of Saccharomyces cerevisiae
Holly C. McQueary, Megan G. Behringer, … David W. Hall·bioRxiv·Dec 1, 2020
- Dosage responses of aneuploid autosomal chromosomes
Natali Papanicolaou, Sebastian Wettersten, … Björn Reinius·bioRxiv·Sep 18, 2025
- On the rate of aneuploidy reversion in a wild yeast model
James Hose, Qi Zhang, … Audrey P. Gasch·bioRxiv·Sep 23, 2024
- Genetic variation in aneuploidy prevalence and tolerance across the Saccharomyces cerevisiae phylogeny
Eduardo Scopel Ferreira da Costa, James Hose, … Audrey P. Gasch·GeneticsPeer-reviewed·Feb 3, 2021
- Dissecting aneuploidy phenotypes by constructing Sc2.0 chromosome VII and SCRaMbLEing synthetic disomic yeast
Yue Shen, Feng Gao, … Yizhi Cai·Cell GenomicsPeer-reviewed·Nov 1, 2023
- Extensive protein dosage compensation in aneuploid human cancers
Klaske M. Schukken, Jason M. Sheltzer·bioRxiv·Jun 18, 2021